AK119
- Generic Name
- AK119
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
Akeso, Inc. (9926.HK) Stock Price, News, Quote & History
Akeso, Inc. develops antibody drugs targeting various cancers and diseases, including AK104 for cervical and lung cancers, AK112 for NSCLC and TNBC, and AK117 for leukemia and solid tumors. It also works on treatments for hypercholesterolemia, psoriasis, and atopic dermatitis, collaborating with major pharmaceutical companies.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath